Literature DB >> 7639339

Topographic abnormalities of proinsulin to insulin conversion in functioning human insulinomas. Comparison of immunoelectron microscopic and clinical data.

J Roth1, P Komminoth, P U Heitz.   

Abstract

It has been proposed that the major defect in human insulinomas is a decreased hormone storage capacity resulting in uncontrolled release of proinsulin and insulin. By immunoelectron microscopy with monoclonal antibodies we studied the subcellular distribution of proinsulin and insulin in benign and malignant functioning insulinomas of different histology and compared the findings with various clinical and pathohistological parameters. We found that, in contrast to normal B cells, the proinsulin to insulin conversion in insulinomas occurs already in the trans Golgi apparatus but remains incomplete, resulting in the formation of secretory granules containing both proinsulin and insulin. Thus, in functioning insulinomas, sorting into secretory granules is not a prerequisite for hormone conversion. Furthermore, proinsulin and insulin storage and most probably subsequent secretion occurs through the secretory granules via the regulated pathway. A substantial variability for both proinsulin and insulin immunolabeling in secretory granules was found not only in individual tumor cells but also among the insulinomas studied. This observed variability may account for the lack of correlation between pathohistological, immunohistochemical, and clinical parameters in functioning insulinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639339      PMCID: PMC1869814     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Ultrastructural localization of intracellular antigens by the use of protein A-gold complex.

Authors:  J Roth; M Bendayan; L Orci
Journal:  J Histochem Cytochem       Date:  1978-12       Impact factor: 2.479

2.  Enhancement of structural preservation and immunocytochemical staining in low temperature embedded pancreatic tissue.

Authors:  J Roth; M Bendayan; E Carlemalm; W Villiger; M Garavito
Journal:  J Histochem Cytochem       Date:  1981-05       Impact factor: 2.479

3.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

4.  Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin.

Authors:  P A Gruppuso; P Gorden; C R Kahn; M Cornblath; W P Zeller; R Schwartz
Journal:  N Engl J Med       Date:  1984-09-06       Impact factor: 91.245

5.  Familial hyperproinsulinemia. An autosomal dominant defect.

Authors:  K H Gabbay; K DeLuca; J N Fisher; M E Mako; A H Rubenstein
Journal:  N Engl J Med       Date:  1976-04-22       Impact factor: 91.245

6.  The production and characterization of monoclonal antibodies specific for human proinsulin using a sensitive microdot assay procedure.

Authors:  O D Madsen; R M Cohen; F W Fitch; A H Rubenstein; D F Steiner
Journal:  Endocrinology       Date:  1983-12       Impact factor: 4.736

7.  Inhibition of proinsulin to insulin conversion in rat islets using arginine and lysine analogs. Lack of effect on rate of release of modified products.

Authors:  P A Halban
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

8.  Functional and morphologic characterization of human insulinomas.

Authors:  M Berger; C Bordi; H J Cüppers; P Berchtold; F A Gries; H Münterfering; R Sailer; H Zimmermann; L Orci
Journal:  Diabetes       Date:  1983-10       Impact factor: 9.461

9.  Proinsulin-like component of circulating insulin in the basal state and in patients and hamsters with islet cell tumors.

Authors:  P Gorden; B Sherman; J Roth
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

10.  pH-independent and -dependent cleavage of proinsulin in the same secretory vesicle.

Authors:  L Orci; P Halban; A Perrelet; M Amherdt; M Ravazzola; R G Anderson
Journal:  J Cell Biol       Date:  1994-09       Impact factor: 10.539

View more
  8 in total

Review 1.  Applications of immunogold and lectin-gold labeling in tumor research and diagnosis.

Authors:  J Roth; C Zuber; P Komminoth; T Sata; W P Li; P U Heitz
Journal:  Histochem Cell Biol       Date:  1996-07       Impact factor: 4.304

2.  Diagnosis and surgical management of insulinomas in 33 consecutive patients at a single institution.

Authors:  Jishu Wei; Xinchun Liu; Junli Wu; Wenbin Xu; Wentao Gao; Kuirong Jiang; Zhihong Zhang; Yi Miao
Journal:  Langenbecks Arch Surg       Date:  2016-08-19       Impact factor: 3.445

3.  Immunocytochemical localization of prohormone convertase 1/3 and 2 in gastrointestinal carcinoids.

Authors:  T Tomita
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties.

Authors:  P Wiesli; C Schmid; A Perren; T Pfammatter; G A Spinas; U Keller
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

5.  Immunocytochemical Localization of Prohormone Convertase 1/3 and 2 in Thyroid C-Cells and Medullary Thyroid Carcinomas.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

6.  Human Insulinomas: Clinical, Cellular, and Molecular Aspects.

Authors:  Paul Komminoth; Philipp U. Heitz; Jürgen Roth
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

7.  Proprotein-Processing Endoprotease Furin and its Substrate Parathyroid Hormone-Related Protein Are Coexpressed in Insulinoma Cells.

Authors:  Yoshie Sawada; Toru Kameya; Toru Aizama; Tetsuro Izumi; Toshiyuki Takeuchi
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

8.  Multiple proinsulin-secreting tumors of the pancreas treated by laparoscopic distal pancreatectomy and splenectomy.

Authors:  Gary Clark; Craig Sadur; Balaram Puligandla
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.